RT Journal Article
SR Electronic
T1 A method to reduce ELISA serial dilution assay workload applied to SARS-CoV-2 and seasonal HCoVs
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263523
DO 10.1101/2021.09.13.21263523
A1 Pattinson, David
A1 Jester, Peter
A1 Guan, Lizheng
A1 Yamayoshi, Seiya
A1 Chiba, Shiho
A1 Presler, Robert
A1 Rao, Hongyu
A1 Iwatsuki-Horimoto, Kiyoko
A1 Ikeda, Nobuhiro
A1 Hagihara, Masao
A1 Uchida, Tomoyuki
A1 Mitamura, Keiko
A1 Halfmann, Peter
A1 Neumann, Gabriele
A1 Kawaoka, Yoshihiro
YR 2021
UL http://medrxiv.org/content/early/2021/09/21/2021.09.13.21263523.abstract
AB Objectives Assays using ELISA measurements on serially diluted serum samples have been heavily used to measure serum reactivity to SARS-CoV-2 antigens and are widely used in virology and elsewhere in biology. We test a method to reduce the workload of these assays, and measure reactivity of SARS-CoV-2 and HCoV antigens to human serum samples collected before and during the COVID-19 pandemic.Methods We apply Bayesian hierarchical modelling to ELISA measurements of human serum samples against SARS-CoV-2 and HCoV antigens.Results Inflection titers for SARS-CoV-2 full-length spike protein (S1S2), spike protein receptor-binding domain (RBD), and nucleoprotein (N) inferred from three spread-out dilutions correlated with those inferred from eight consecutive dilutions with an R2 value of 0.97 or higher. We confirm existing findings showing a small proportion of pre-pandemic human serum samples contain cross-reactive antibodies to SARS-CoV-2 S1S2 and N, and that SARS-CoV-2 infection increases serum reactivity to the beta-HCoVs OC43 and HKU1 S1S2.Conclusions In serial dilution assays, large savings in resources and/or increases in throughput can be achieved by reducing the number of dilutions measured and using Bayesian hierarchical modelling to infer inflection or endpoint titers. We have released software for conducting these types of analysis.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the US Centers for Disease Control and Prevention [grant number: 75D30120C09259]; and the Japan Agency for Medical Research and Development [grant numbers: 20fk0108301, 20fk0108527, 20fk0108272].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Wisconsin: The study was approved by the Human Subjects Institutional Review Boards at the University of Wisconsin and signed informed consent was obtained from each participant at each time point before collection. MCRI: Human samples were collected after informed consent by protocols approved by the MCRI Institutional Review Board. IMSUT: Human samples were collected by following protocols approved by the Research Ethics Review Committee of the Institute of Medical Science, the University of Tokyo (approval number 2019-71-0201).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available on request.